Aptose Bioscienc Financials
This page shows Aptose Bioscienc (APTOF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cash burn rather than self-funded operations is the core mechanic here, with external financing sustaining the research platform.
FY2025's free cash burn improved to-$22.0M from-$36.0M in FY2024, but that cleaner cash-flow picture did not strengthen liquidity. Cash on hand ended at just$935K while total liabilities reached$37.2M , indicating the reset lowered spending yet left the company reliant on financing and accrued obligations rather than rebuilt reserves.
The cost base has been deliberately compressed: R&D fell from
This is not a capital-equipment story: capital spending was only
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Aptose Bioscienc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aptose Bioscienc carries a low D/E ratio of -1.37, meaning only $-1.37 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
Aptose Bioscienc's current ratio of 0.69 is below the typical benchmark, resulting in a score of 8/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Aptose Bioscienc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Aptose Bioscienc generates $0.86 in operating cash flow (-$22.0M OCF vs -$25.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Aptose Bioscienc generated $0 in revenue in fiscal year 2025.
Aptose Bioscienc reported -$25.5M in net income in fiscal year 2025. This represents a decrease of 0.1% from the prior year.
Aptose Bioscienc earned $-10.41 per diluted share (EPS) in fiscal year 2025. This represents an increase of 71.4% from the prior year.
Cash & Balance Sheet
Aptose Bioscienc generated -$22.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 38.9% from the prior year.
Aptose Bioscienc held $935K in cash against $0 in long-term debt as of fiscal year 2025.
Aptose Bioscienc had 3M shares outstanding in fiscal year 2025. This represents an increase of 27.2% from the prior year.
Margins & Returns
Capital Allocation
Aptose Bioscienc invested $11.3M in research and development in fiscal year 2025. This represents a decrease of 24.9% from the prior year.
Aptose Bioscienc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
APTOF Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $3.6M | N/A | $2.2M-33.1% | $3.3M+39.5% | $2.4M | N/A | $4.7M+6.5% | $4.4M |
| SG&A Expenses | $3.6M | N/A | $2.7M-25.3% | $3.6M+17.0% | $3.1M | N/A | $2.3M-22.8% | $2.9M |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | -$212K-92.7% | -$110K-31.0% | -$84K | N/A | $12K-87.1% | $93K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$7.6M | N/A | -$5.1M+27.3% | -$7.0M-27.1% | -$5.5M | N/A | -$7.0M+4.1% | -$7.3M |
| EPS (Diluted) | $-2.99 | N/A | $-2.01+27.2% | $-2.76-5.7% | $-2.61 | N/A | $-11.33+12.8% | $-12.99 |
APTOF Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.7M+7.1% | $10.0M+57.9% | $6.3M+13.4% | $5.6M-25.1% | $7.5M-26.3% | $10.1M-7.3% | $10.9M-0.2% | $10.9M |
| Current Assets | $6.2M-4.5% | $6.4M+70.7% | $3.8M+15.5% | $3.3M-53.1% | $7.0M-26.9% | $9.5M-6.9% | $10.2M+0.7% | $10.2M |
| Cash & Equivalents | $4.1M+338.5% | $935K+52.5% | $613K+10.8% | $553K-88.3% | $4.7M-22.9% | $6.2M-22.7% | $8.0M-4.4% | $8.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $45.4M+22.1% | $37.2M+44.2% | $25.8M+29.2% | $20.0M+34.3% | $14.9M+1.3% | $14.7M-26.9% | $20.1M+52.9% | $13.1M |
| Current Liabilities | $11.2M+20.8% | $9.3M+31.5% | $7.1M-21.3% | $9.0M+42.5% | $6.3M+41.7% | $4.5M-54.3% | $9.8M-23.2% | $12.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$34.7M-27.6% | -$27.2M-39.7% | -$19.4M-35.3% | -$14.4M-94.4% | -$7.4M-62.7% | -$4.5M+50.3% | -$9.1M-319.8% | -$2.2M |
| Retained Earnings | -$574.1M-1.3% | -$566.4M-1.4% | -$558.7M-0.9% | -$553.6M-1.3% | -$546.5M-1.0% | -$541.0M-0.3% | -$539.4M-1.3% | -$532.4M |
APTOF Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.8M0.0% | -$5.8M+21.2% | -$7.4M-24.7% | -$5.9M-112.6% | -$2.8M+65.3% | -$8.1M+22.3% | -$10.4M-79.6% | -$5.8M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% | $2.0M |
| Financing Cash Flow | $5.8M-29.5% | $8.3M+7.1% | $7.8M+210.0% | $2.5M+201.6% | $829K-87.8% | $6.8M-32.0% | $10.0M+110.5% | $4.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
APTOF Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -71.2% | N/A | -80.8%+45.2pp | -126.0%-51.7pp | -74.2% | N/A | -63.6%+2.6pp | -66.2% |
| Current Ratio | 0.55-0.1 | 0.69+0.2 | 0.53+0.2 | 0.36-0.7 | 1.10-1.0 | 2.14+1.1 | 1.05+0.2 | 0.80 |
| Debt-to-Equity | -1.31+0.1 | -1.37-0.0 | -1.33+0.1 | -1.39+0.6 | -2.01+1.2 | -3.23-1.0 | -2.20+3.8 | -6.03 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$27.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.69), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Aptose Bioscienc's annual revenue?
Aptose Bioscienc (APTOF) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Aptose Bioscienc profitable?
No, Aptose Bioscienc (APTOF) reported a net income of -$25.5M in fiscal year 2025.
What is Aptose Bioscienc's free cash flow?
Aptose Bioscienc (APTOF) generated -$22.0M in free cash flow during fiscal year 2025. This represents a 38.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Aptose Bioscienc's operating cash flow?
Aptose Bioscienc (APTOF) generated -$22.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aptose Bioscienc's total assets?
Aptose Bioscienc (APTOF) had $10.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Aptose Bioscienc's capital expenditures?
Aptose Bioscienc (APTOF) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Aptose Bioscienc spend on research and development?
Aptose Bioscienc (APTOF) invested $11.3M in research and development during fiscal year 2025.
What is Aptose Bioscienc's current ratio?
Aptose Bioscienc (APTOF) had a current ratio of 0.69 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Aptose Bioscienc's debt-to-equity ratio?
Aptose Bioscienc (APTOF) had a debt-to-equity ratio of -1.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aptose Bioscienc's return on assets (ROA)?
Aptose Bioscienc (APTOF) had a return on assets of -254.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aptose Bioscienc's cash runway?
Based on fiscal year 2025 data, Aptose Bioscienc (APTOF) had $935K in cash against an annual operating cash burn of $22.0M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Aptose Bioscienc's debt-to-equity ratio negative or unusual?
Aptose Bioscienc (APTOF) has negative shareholder equity of -$27.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Aptose Bioscienc's Piotroski F-Score?
Aptose Bioscienc (APTOF) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aptose Bioscienc's earnings high quality?
Aptose Bioscienc (APTOF) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Aptose Bioscienc?
Aptose Bioscienc (APTOF) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.